The type and quality of end‐of‐life care varies greatly in ALS; the time to initiate end‐of‐life
care is not defined, and decision making is hampered by logistical and financial barriers …

Amyotrophic lateral sclerosis (ALS) is characterized by upper and lower motor neuron
dysfunction and loss, rapidly progressive muscle weakness, wasting and death,,. Many …

Background Amyotrophic lateral sclerosis (ALS) is a fatal and incurable neurodegenerative
disease. There is still no established cost-effective treatment that can improve functional …

Background Amyotrophic lateral sclerosis (ALS) is a disease caused by motor neuron
degeneration. Recently, a novel SIGMAR1 gene variant (p. E102Q) was discovered in some …

Amyotrophic lateral sclerosis (ALS) is a progressively debilitating neurodegenerative
condition that occurs in adulthood and targets the motor neurons. Social support is crucial to …

In patients with intermediate or high grade non-Hodgkin lymphoma (NHL), third generation
chemotherapy regimens have been introduced to improve survival in comparison with the …

Our objective was to estimate the economic burden of patients with amyotrophic lateral
sclerosis (ALS) and to examine the effect of treatment in a multidisciplinary ALS treatment …

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that imposes a
great burden on the patient, the patient's family and society. However, we lack information …

Abstract Formation of Cu, Zn superoxide dismutase 1 (SOD1) protein inclusions within motor
neurons is one of the principal characteristics of SOD1-related amyotrophic lateral sclerosis …

Objective In economic evaluation, a commonly used outcome measure for the treatment
effect is the between-arm difference in restricted mean survival time (rmstD). This study …